【摘要】 目的 浅析非奈利酮对成人隐匿性自身免疫性糖尿病(LADA)肾病(Ⅲ期)的临床疗效。方法 招募本院2023年1月至2025年7月收治的LADA肾病Ⅲ期患者作为研究样本,非盲法下以随机数字表法将80例患者分为对照组(常规治疗)、观察组(常规治疗基础上加用非奈利酮)各40例,比较两组血清肌酐(Scr)、尿素氮(BUN)、尿微量白蛋白(mALB)、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2h血糖(2hPG)、免疫球蛋白(Ig)A、IgG、IgM、治疗有效率和不良反应差异。结果 治疗前,两组Scr、BUN、mALB、HbA1c、FPG、2hPG、IgA、IgG、IgM比较,差异无统计学意义(P>0.05);治疗后,观察组Scr、BUN、mALB水平均低于对照组,HbA1c、FPG、2hPG水平亦均低于对照组,IgA、IgG、IgM水平均高于对照组,差异有统计学意义(P<0.05)。且观察组治疗有效率高于对照组,差异有统计学意义(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论 常规治疗基础上加用非奈利酮治疗LADA肾病Ⅲ期,能更好地改善患者糖尿病病情,提高肾功能,整体疗效显著,且用药安全性良好。更多还原

【Abstract】 Objective To evaluate the clinical efficacy of Norelone in treating adult-onset latent autoimmune diabetes(LADA) nephropathy(stage Ⅲ). Methods A total of 80 patients with stage Ⅲ LADA nephropathy admitted to our hospital between January 2023 and July 2025 were enrolled as study subjects. Using a randomized digital table without blinding, the patients were divided into two groups: the control group(standard treatment) and the observation group(standard treatment combined with Norelone), each consisting of 40 patients. The differences in serum creatinine(Scr), blood urea nitrogen(BUN), urinary microalbumin(mALB), glycated hemoglobin(HbA1c), fasting glucose(FPG), postprandial 2h glucose(2hPG), immunoglobulins(IgA, IgG, IgM), treatment efficacy rates, and adverse reactions were compared. Results Pre-treatment analysis showed no statistically significant differences in Scr, BUN, mALB, HbA1c, FPG, 2hPG, IgA, IgG, or IgM between the groups(P>0.05). Post-treatment analysis revealed that the observation group had significantly lower Scr, BUN, and mALB levels than the control group, while HbA1c, FPG, and 2hPG were also reduced. Conversely, IgA, IgG, and IgM levels were higher in the observation group, with statistically significant differences(P<0.05). The treatment efficacy rate was higher in the observation group compared to the control group(P<0.05). No statistically significant differences were observed in adverse reactions between the groups(P>0.05). Conclusion The addition of nonanriton to conventional treatment for stage Ⅲ LADA nephropathy can better improve the diabetic condition of patients, improve renal function, and achieve significant overall efficacy and good safety.更多还原